Pidilizumab (CT-011) is the first PD-1-targeting humanized mAb to be tested in clinical trials for melanoma, NSCLC, renal cell carcinoma, head and neck cancers, lymphoma and several other cancers 70. The gene discussed is PDCD1; the disease is hereditary clear cell renal cell carcinoma.